OBJECTIVES: To use a discrete choice experiment (DCE) to determine patient preferences for the treatment features of dulaglutide 1.5 mg vs insulin glargine (Lantus SoloStar®) among people with type 2 diabetes mellitus (T2DM) in the United Kingdom (UK).

METHODS: In-person interviews were conducted among people in the UK with self-reported T2DM, naïve to treatment with injectable diabetes medications. The DCE examined 7 treatment attributes each described by 2 levels: frequency of gastrointestinal side effects, frequency of hypoglycaemia, frequency of pancreatitis, dosing frequency, HbA change, weight change and type of delivery system (deidentified dulaglutide and Lantus SoloStar® devices). Attribute selection was informed by qualitative interviews with people with T2DM treated with oral and/or injectable medications. Part-worth utilities were estimated using random effects logit models and used to calculate relative importance (RI) values for each attribute. Chi-square test was used to determine differences in preferences for dulaglutide vs insulin glargine profiles.

RESULTS: ; change (14.2%), frequency of pancreatitis (12.3%) and frequency of hypoglycaemia (2.2%). The majority of participants preferred the dulaglutide profile (75.0%) compared to the insulin glargine profile (25.0%) (p<.01).

CONCLUSIONS: This study elicited UK patients’ preferences for attributes and levels representing the actual characteristics of dulaglutide and insulin glargine (Lantus SoloStar®). Of the attributes tested, no one attribute highly drove patients’ preferences. The majority of participants preferred the dulaglutide profile over the insulin glargine profile. The results will help treatment providers understand the clinical and non-clinical factors influencing preferences of people with T2DM, naïve to injectable diabetes medications, when considering next treatment options.